People who live past 110 carry a strange immune cell: a helper T cell that acts like a killer. It makes up about 18% of their T cells, over 4 times the share seen in people in their 70s to 90s. And its receptors match ones found in lung tumors. A new Cell Reports study asks whether these cells help explain how they got there. Researchers from Keio University, RIKEN, and the University of Osaka profiled T cells from 28 Japanese donors: 8 in their 70s to 90s, 10 centenarians, and 10 supercentenarians (110 or older). They analyzed over 43,000 cells, tracking gene activity, surface proteins, and each cell's receptor. First, a quick primer on the immune cells involved. T cells are immune cells that patrol your body. CD4 T cells are usually helpers. They coordinate the immune response rather than kill anything directly. CD4 CTLs are an unusual subset that turn into killers, releasing toxic molecules like granzymes that destroy infected or abnormal cells. In most adults they're rare, under 5% of T cells. Every T cell carries a receptor that recognizes one specific target. Cells that share the same receptor are a clone. When a clone gets repeatedly stimulated by the same target, it multiplies. What they found: • CD4 killer cells rose with age. Median share of T cells was 4.0% in the 70s to 90s group, 9.6% in centenarians, and 17.6% in supercentenarians. • Helpers convert to killers in steps. Cells first lose a marker called CD27, then CD28. The in-between state (CD27 negative, CD28 positive) made up 10.5% of CD4 T cells, while the reverse order was under 0.3%. • The cells weren't worn out. They stayed negative for PD-1, a marker of exhaustion, and had low levels of other exhaustion genes. They look highly specialized, not depleted. • A few clones dominated. The single largest clone made up 33.3% of CD4 killer cells on average. In one centenarian, one clone was 126 of 234 cells. That pattern points to repeated stimulation by a persistent target. • The dominant clones were private. No two people shared the same top receptor, which suggests each person's cells were responding to their own targets. • One clone, many roles. After lab stimulation, cells from the same clone split into groups producing different signaling molecules, including types linked to antibody help, immune suppression, and allergic-type responses. All of them still made the inflammatory molecules IFN-gamma and TNF-alpha. Then the cancer angle. The authors searched a database of over 690 million receptor sequences. Of the top clones that matched, 32 of the 36 expanded matches came from cancer patients, mostly lung cancer (17). But none of the supercentenarians or centenarians had a history of lung, breast, or liver cancer. The team suggest these cells may be responding to something subclinical, such as early abnormal cells, senescent cells, or reactivated latent viruses. Earlier work showed CD4 killer cells can clear senescent cells in aged skin and suppress tumors in mouse models. Some very important limits here: Only 28 people were studied, and the cells came from blood, not tissues, so we don't know what they actually target. This study didn't test whether these cells kill cancer cells. The database matches rest on one receptor chain and show overlap, not proof of the same target. The cytokine results come from lab stimulation. The authors also note these cells cut both ways. In other settings, they're linked to autoimmune disease, cardiovascular disease, and excess inflammation. Whether they help or harm may depend on how well inflammation is kept in check. Still, it points to a possible feature of aging well: an immune system that shifts from broad coverage toward focusing on the threats it has already learned to recognize. For longevity, the idea that immune aging is only decline may be too simple. These cells looked specialized, not exhausted. But these are people who already reached 110, so it's unclear whether the cells helped them get there or simply reflect an immune system that aged well. That second point is my inference, not something the study tested. Immune function at 100 likely reflects decades of exposures, inflammation, and repair, and how well those were managed from midlife on.